Ironwood Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced the U.S. Food and Drug Administration (FDA) had granted its olinciguat (IW-1701) Orphan Drug Designation for sickle cell disease. The FDA’s Office of … Continue Reading Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer. While at Biogen, O’Neill held various leadership roles in Alzheimer’s … Continue Reading Biogen’s O’Neill Heads to Sarepta Therapeutics
Danish company Novo Nordisk is reportedly considering cost-cutting plans that would cut up to 3,000 jobs. Originally reported in the Danish publication Borsen, Novo Nordisk’s management and board of directors … Continue Reading Novo Nordisk Considers Cutting Up to 3,000 Jobs
The Bill & Melinda Gates Foundation has spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston. Although it found its temporary space … Continue Reading Bill and Melinda Gates Foundation Spins Out a Nonprofit Biotech Company
CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
A new pharma Twitter influencer survey ranks Pfizer and GSK at the top, with Teva and Merck at the bottom. Tweeting to the top, GlaxoSmithKline and Pfizer tied for the … Continue Reading GSK, Pfizer lead in new global Twitter pharma influencer ranking
Social media graph from Ogilvy Healthworld annual research report plots pharma company engagement across number of posts in 2017. (Ogilvy Healthworld) Pharma companies are maturing on social media, if Ogilvy … Continue Reading Pharma’s social media strategies are growing up—and working better, too, report finds
Sanofi could have just let it go. When actress Roseanne Barr blamed its sleep aid Ambien for a racist post, the pharma company could have simply ignored it and let … Continue Reading Want to score on social, pharma? Follow Sanofi’s lead, experts say
Oncology DTC advertising has soared in recent years, thanks to new drugs and mechanisms of action. (Syneos Health) As more oncology treatments have flooded the market, so has cancer DTC … Continue Reading New drugs, new money: Surge in cancer DTC ads follows wave of I-O debuts
AstraZeneca’s Lynparza is working its way toward becoming the first PARP inhibitor approved in prostate cancer. (AstraZeneca) CHICAGO—At last year’s American Society of Clinical Oncology annual meeting, AstraZeneca posted Lynparza … Continue Reading ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
Gilead Sciences wants people to get honest about HIV and sex. In new TV awareness ads, actors talk “honestly” about fearing HIV testing and using—or not using—condoms for protection. And one of the … Continue Reading Gilead takes HIV prevention message to TV, pushing PreP awareness with hipster ad
While Humira held its ad spending crown yet again in May, Latuda jumped up to knock Lyrica from the No. 2 spot it’s held for the past few months. Sunovion … Continue Reading In May TV spending, Sunovion jumps to 2nd, but AbbVie easily keeps top spot
Pharma TV ads are happier than ever, according to new research, but that may not be a good thing for patients. Researchers found that DTC product ads on TV are … Continue Reading Pharma ads are sunnier than they used to be. But are they better?
In many ways, 2017 was an uncertain year for biopharma as a new, erratic administration entered the White House and federal government. The industry came under fire early with then-President-elect Donald Trump’s comments … Continue Reading The top 15 pharma companies by 2017 revenue
CHICAGO—Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it … Continue Reading ASCO: Merck’s solo Keytruda wins again, but might just leave room for competition
CHICAGO—Novartis’ breast cancer drug Kisqali so far hasn’t lived up to expectations, and the drugmaker’s hoping some strong new data in metastatic patients will help. Can the numbers actually boost … Continue Reading ASCO: Novartis makes a case for earlier Kisqali use. Will ‘conservative’ docs run with it?